Project cooperation
ASC1R is an oligonucleotide-based therapeutic developed on the ESiNAR-X platform, targeting the SARS-CoV-2 RNA virus and intended for critically ill patients requiring intensive care to rapidly inhibit viral replication.
CEO
Selecta Biotech SE
Bratislava, Slovakia
I am the CEO of Selecta Biotech SE, a European joint-stock company founded with the ambition to implement a new generation of oligonucleotide therapeutics in clinical practice, with the aim of achieving the desired therapeutic effect without side effects.
Dr Razga has 25+ years of professional experience in oncology, with a biotechnology focus within the last decade. He is trained in Physical and Biomolecular chemistry with primary research interest in RNA structure and function. After working at the National Centre for Biomolecular Research (CZ) he became an associate at Bowling Green State University (Ohio, USA). Dr Razga then accepted a position at the Center of Molecular Biology and Gene Therapy (CZ), and later became a team leader at the Slovak Academy of Sciences with research focus in anticancer therapy.
Dr Razga Holds multiple awards including the Award of the Ministry of Education, Youth and Sports of the Czech Republic and the Award of the Slovak Academy of Sciences and had been the recipient of the prestigious international Marie Skłodowska-Curie Fellowship.
Project cooperation
ASC1R is an oligonucleotide-based therapeutic developed on the ESiNAR-X platform, targeting the SARS-CoV-2 RNA virus and intended for critically ill patients requiring intensive care to rapidly inhibit viral replication.
Project cooperation
ASP210 is a therapeutic oligonucleotide leveraging the ESiNAR-X platform to target BCR-ABL1 mRNA in patients with chronic myeloid leukemia who are resistant or refractory to TKI therapy.
Project cooperation
ASPER2 is a therapeutic oligonucleotide based on the ESiNAR-X platform, intended for patients with gradually progressive chronic kidney disease accompanied by renal fibrosis.